Viva Biotech Shanghai

Viva Biotech announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan has been completed.

FAST NEWS: Viva Biotech completes Langhua Pharma buyout

The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…

Recent Articles

RELATED ARTICLES

  1. GenScript reports reduced losses amid cell therapy growth potential
    GenScript losses shrink on strong growth for cancer cell therapy 
    1548.HK
  2. HBM gets health boost from drug licensing deals
    2142.HK
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Profit setback for Simcere Pharma in novel drugs quest
    2096.HK
  5. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva